Glass Mitchell 4

What Happened

• Glass Mitchell, Chief Medical Officer and a director of Q/C Technologies (QCLS), was granted a derivative award of 50,000 stock options on 2026-04-13. The Form 4 records the acquisition price as $0.00 (a grant), so no cash was paid at grant and no shares were immediately transferred.

Key Details

• Transaction date: 2026-04-13; reported on Form 4 filed 2026-04-15 (timely).
• Transaction type/code: Grant/Award (A) of a derivative (stock options).
• Quantity: 50,000 options; reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the filing.
• Footnote: The stock options are subject to expiration if the reporting person ceases to be employed by or provide services to the issuer.

Context

• This was an options grant (a derivative award), not an immediate purchase of common shares. Options must generally be exercised (and may be subject to vesting and an exercise price) before they convert into actual shares; the filing does not state exercise price or vesting details.
• Grants like this are common as compensation for executives and directors; they do not by themselves indicate buying or selling of stock or immediate cash value.